However, little is known about how chemotherapy use and oncologists' recommendations have changed in recent years.We surveyed 5080 women (70% response rate) diagnosed with breast cancer between 2013 and 2015 and accrued through two Surveillance, Epidemiology, and End Results registries (Georgia and Los Angeles) about chemotherapy receipt and their oncologists' chemotherapy recommendations. Hartman, A., Kurian, A. W., Mills, M. A., et al, Results from a pilot breast cancer screening trial using a combination of clincal breast exam, mammography, breast MRI, and ductal lavage in a high-risk population, Freeman Spogli Institute for International Studies, Institute for Computational and Mathematical Engineering (ICME), Institute for Human-Centered Artificial Intelligence (HAI), Institute for Stem Cell Biology and Regenerative Medicine, Stanford Institute for Economic Policy Research (SIEPR), Stanford Woods Institute for the Environment, Office of VP for University Human Resources, Office of Vice President for Business Affairs and Chief Financial Officer, Directed Reading in Health Research and Policy, DOI 10.1016/j.currproblcancer.2016.09.007. View details for DOI 10.1007/s10549-022-06656-7, Genetic testing is widespread among breast cancer patients; however, no guideline recommends using germline genetic testing results to select a chemotherapy regimen. All statistical tests were two-sided.The analytic sample was 2926 patients with stage I-II, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. A search engine designed to express complex electronic phenotypes from longitudinal patient records enables the identification of variability in patient care, helping to define disparities and areas for improvement. We analysed rare CNVs in genes and non-coding regions for 86,788 breast cancer cases and 76,122 controls of European ancestry with genome-wide array data. We compared BRCA mutation position, cancer history, hormonal and reproductive exposures. The goal of this study was to determine the effect on overall survival and progression free Expanding and validating this approach in both additional cross-sectional and longitudinal cohorts may enable improved risk stratification and risk-appropriate treatment in DCIS. The Accuracy of BRCA1/2 Mutation Prediction Models in Different Ethnicity and Gender: Experience in a Chinese Cohort, Kwong, A., Wong, C., Suen, D., Choi, C., Wong, C., Law, F., Kurian, A. W., et al, A High Percentage of Triple Negative Tumors Present as Palpable Masses. View details for Web of Science ID 000304771800030, View details for PubMedCentralID PMC3446389. Luhn, P., O'Hear, C., Ton, T. G., Hsieh, A., Yi, J., Chang, C. W., Funke, R., Kurian, A. W. Molecular receptor profiles in male mutation carriers with breast cancer. Katz, S., Hawley, S. T., Tocco, R., Kurian, A. W. Change in practice of RRSO consults and procedures during the COVID-19 pandemic. B., Eliassen, A. H., Eriksson, M. n., Evans, D. G., Fasching, P. A., Figueroa, J. n., Fritschi, L. n., Gabrielson, M. n., Gago-Dominguez, M. n., Gao, C. n., Gapstur, S. M., Gaudet, M. M., Giles, G. G., Gonzlez-Neira, A. n., Gunel, P. n., Haeberle, L. n., Haiman, C. A., Hkansson, N. n., Hall, P. n., Hamann, U. n., Hatse, S. n., Heyworth, J. n., Holleczek, B. n., Hoover, R. N., Hopper, J. L., Howell, A. n., Hunter, D. J., John, E. M., Jones, M. E., Kaaks, R. n., Keeman, R. n., Kitahara, C. M., Ko, Y. D., Koutros, S. n., Kurian, A. W., Lambrechts, D. n., Marchand, L. L., Lee, E. n., Lejbkowicz, F. n., Linet, M. n., Lissowska, J. n., Llaneza, A. n., MacInnis, R. J., Martinez, M. E., Maurer, T. n., McLean, C. n., Neuhausen, S. L., Newman, W. G., Norman, A. n., O'Brien, K. M., Olshan, A. F., Olson, J. E., Olsson, H. n., Orr, N. n., Perou, C. M., Pita, G. n., Polley, E. C., Prentice, R. L., Rennert, G. n., Rennert, H. S., Ruddy, K. J., Sandler, D. P., Saunders, C. n., Schoemaker, M. J., Schttker, B. n., Schumacher, F. n., Scott, C. n., Scott, R. J., Shu, X. O., Smeets, A. n., Southey, M. C., Spinelli, J. J., Stone, J. n., Swerdlow, A. J., Tamimi, R. M., Taylor, J. (Am J Public Health. View details for PubMedID 31200352, View details for DOI 10.6004/jnccn.2018.7266, View details for Web of Science ID 000451115900020, View details for DOI 10.1001/jamaoncol.2018.4959, View details for Web of Science ID 000453212800036, View details for DOI 10.1158/1055-9965.EPI-17-1129, View details for Web of Science ID 000448896500013. compared with a placebo in treating postmenopausal women who have received hormone therapy Of 945 women who worried about finances, 679 (72.8%) indicated that physicians and their staff did not help. To the authors' knowledge, the magnitude of benefit is unknown.The authors used data from the Surveillance, Epidemiology, and End Results (SEER) program regarding all women diagnosed with American Joint Committee on Cancer stage 0 to stage III unilateral breast cancer in California from 1998 through 2015 and treated with BLM versus breast-conserving therapy including surgery and radiotherapy (BCT) or unilateral mastectomy (ULM). However, when restricting to diagnoses 1996 or later and adjusting for a larger set of covariates, risk was attenuated (HR 0.86, 95% CI 0.52-1.42).Among California breast cancer patients diagnosed from 1988-2013, nipple-sparing mastectomy was not associated with worse survival than non-nipple-sparing mastectomy. pharmacokinetic (PK) cohort of the study (cohort A) in postmenopausal women with metastatic Wu, J., Cao, G., Sun, X., Lee, J., Rubin, D. L., Napel, S., Kurian, A. W., Daniel, B. L., Li, R. Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. A., Teo, S. H., Teras, L. R., Toland, A. E., Tollenaar, R. A., Torres, D., Torres-Meja, G., Troester, M. A., Truong, T., Vachon, C. M., Vijai, J., Weinberg, C. R., Wendt, C., Winqvist, R., Wolk, A., Wu, A. H., Yamaji, T., Yang, X. R., Yu, J. C., Zheng, W., Ziogas, A., Ziv, E., Dunning, A. M., Easton, D. F., Hemingway, H., Hamann, U., Kuchenbaecker, K. B. Kurian, A. W., Abrahamse, P., Bondarenko, I., Hamilton, A. S., Deapen, D., Gomez, S. L., Morrow, M., Berek, J. S., Hofer, T. P., Katz, S. J., Ward, K. C. Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer. determined in previous studies of participants with mBC and the safety data to date suggest We identified de novo MBC patients from CCR and extracted information on distant recurrences from patient notes in EMR. The adjusted percentage treated and adjusted odds ratio (OR) are reported based on multivariable modeling for each treatment-eligible group.A total of 20568 women (17.3%) of 119198 were eligible (mean [SD] age, 51.4 [12.2]). Here, weestablish an invitro model for BRCA2-crisis that demonstrates chromatin remodeling and activation of an NF-B survival pathway in response to transient BRCA2 depletion. Several machine learning approaches have been developed for recurrence prediction in previous studies, but most of them use only structured electronic health records and only a small training dataset, with limited success in clinical application. Stanford is currently not accepting patients for this trial. The current standard is for patients to contact and encourage relatives (patient-mediated contact) to undergo counseling and testing. He reports to . The prevalence in risk factors was similar between foreign-born and U.S.-born women in the younger birth cohort, and did not fully explain the observed associations with birthplace and other migration characteristics.In contrast to studies from earlier decades, younger foreign-born Asian American women had a higher risk of breast cancer than U.S.-born Asian American women.It is important and urgent to understand what factors drive the increasing burden of breast cancer in women of Asian descent and implement effective prevention programs. Patient-reported toxicities help to appraise the breast cancer treatment experience. However, past statin users were not at lower risk of cancer death compared with never-users (HR, 1.06; 95% CI, 0.85-1.33); in addition, statin use was not associated with a reduction of overall cancer incidence despite its effect on survival (HR, 0.96; 95% CI, 0.92-1.001).In a cohort of postmenopausal women, regular use of statins or other lipid-lowering medications was associated with decreased cancer death, regardless of the type, duration, or potency of statin medications used.British Journal of Cancer advance online publication, 9 June 2016; doi:10.1038/bjc.2016.149 www.bjcancer.com. Using the National Comprehensive Cancer Network's 2013 breast cancer guidelines, the authors assessed the receipt of GCC by cancer subtype among a subset of YAs (n=952). Ductal lavage was attempted in any duct identifiable with a catheter.Ducts were successfully catheterized in 60 of 75 patients (80%). This study describes factors associated with the receipt of guideline-concordant care (GCC) among YAs.The authors identified 1259 YA women with invasive breast cancer diagnosed in 2013 in the National Cancer Institute's Patterns of Care study. View details for DOI 10.1097/COC.0000000000000865. Cronin, K., Petkov, V. I., Howlader, N., Howe, W., Schussler, N. C., Kurian, A. W., Penberthy, L. Relationship between rising bilateral mastectomy rates and increased use of neoadjuvant chemotherapy (NAC) in California, 1998-2012. Gallagher, S., Hughes, E., Kurian, A. W., Domchek, S. M., Garber, J., Probst, B., Morris, B., Tshiaba, P., Meek, S., Rosenthal, E., Roa, B., Slavin, T. P., Wagner, S., Weitzel, J., Gutin, A., Lanchbury, J. S., Robson, M. Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative. View details for PubMedID 30289174. Breast cancer treatment according to pathogenic variants in cancer susceptibility genes in a population-based cohort. Dennis, J., Tyrer, J. P., Walker, L. C., Michailidou, K., Dorling, L., Bolla, M. K., Wang, Q., Ahearn, T. U., Andrulis, I. L., Anton-Culver, H., Antonenkova, N. N., Arndt, V., Aronson, K. J., Freeman, L. E., Beckmann, M. W., Behrens, S., Benitez, J., Bermisheva, M., Bogdanova, N. V., Bojesen, S. E., Brenner, H., Castelao, J. E., Chang-Claude, J., Chenevix-Trench, G., Clarke, C. L., Colle, J. M., Couch, F. J., Cox, A., Cross, S. S., Czene, K., Devilee, P., Drk, T., Dossus, L., Eliassen, A. H., Eriksson, M., Evans, D. G., Fasching, P. A., Figueroa, J., Fletcher, O., Flyger, H., Fritschi, L., Gabrielson, M., Gago-Dominguez, M., Garca-Closas, M., Giles, G. G., Gonzlez-Neira, A., Gunel, P., Hahnen, E., Haiman, C. A., Hall, P., Hollestelle, A., Hoppe, R., Hopper, J. L., Howell, A., Jager, A., Jakubowska, A., John, E. M., Johnson, N., Jones, M. E., Jung, A., Kaaks, R., Keeman, R., Khusnutdinova, E., Kitahara, C. M., Ko, Y. D., Kosma, V. M., Koutros, S., Kraft, P., Kristensen, V. N., Kubelka-Sabit, K., Kurian, A. W., Lacey, J. V., Lambrechts, D., Larson, N. L., Linet, M., Ogrodniczak, A., Mannermaa, A., Manoukian, S., Margolin, S., Mavroudis, D., Milne, R. L., Muranen, T. A., Murphy, R. A., Nevanlinna, H., Olson, J. E., Olsson, H., Park-Simon, T. W., Perou, C. M., Peterlongo, P., Plaseska-Karanfilska, D., Pylks, K., Rennert, G., Saloustros, E., Sandler, D. P., Sawyer, E. J., Schmidt, M. K., Schmutzler, R. K., Shibli, R., Smeets, A., Soucy, P., Southey, M. C., Swerdlow, A. J., Tamimi, R. M., Taylor, J. Recently, a decline in breast cancer incidence was reported in the United States and several other developed countries, and a substantial reduction in menopausal hormone therapy use was proposed as a possible cause. A., Gaudet, M. M., Giles, G. G., Goldberg, M. S., Gonzlez-Neira, A., Alns, G. I., Grip, M., Gunel, P., Haiman, C. A., Hall, P., Hamann, U., Harkness, E. F., Heemskerk-Gerritsen, B. We investigate the relevance of the major histocompatibility complex region in breast cancer susceptibility, using imputed class I and II HLA alleles, in 25,484 women of Asian ancestry.A total of 12,901 breast cancer cases and 12,583 controls from 12 case-control studies were included in our pooled analysis. Breast cancer molecular subtypes defined by joint hormone receptor (HR, estrogen receptor [ER] and/or progesterone receptor [PR]) and HER2 status were assessed. [12][13] Application server software became Oracle's fastest-growing business primarily because of his efforts. By contrast, ATM PV carriers did not have significantly increased CBC risks. Studies on specific cancer types in relation to cancer use have also been mixed, though the most promising results appear to be found in gastrointestinal cancers. Factors that discouraged testing included insurance concerns (14%; 95% CI, 12% to 16%), cost (14%; 95% CI, 12% to 16%), and discrimination (9%; 95% CI, 7% to 11%). A., Ghoussaini, M., Giles, G. G., Goldberg, M. S., Gonzlez-Neira, A., Gunel, P., Gndert, M., Haeberle, L., Hahnen, E., Haiman, C. A., Hall, P., Hamann, U., Hartman, M., Hatse, S., Hauke, J., Hollestelle, A., Hoppe, R., Hopper, J. L., Hou, M. F., Ito, H., Iwasaki, M., Jager, A., Jakubowska, A., Janni, W., John, E. M., Joseph, V., Jung, A., Kaaks, R., Kang, D., Keeman, R., Khusnutdinova, E., Kim, S. W., Kosma, V. M., Kraft, P., Kristensen, V. N., Kubelka-Sabit, K., Kurian, A. W., Kwong, A., Lacey, J. V., Lambrechts, D., Larson, N. L., Larsson, S. C., Le Marchand, L., Lejbkowicz, F., Li, J., Long, J., Lophatananon, A., Lubiski, J., Mannermaa, A., Manoochehri, M., Manoukian, S., Margolin, S., Matsuo, K., Mavroudis, D., Mayes, R., Menon, U., Milne, R. L., Mohd Taib, N. A., Muir, K., Muranen, T. A., Murphy, R. A., Nevanlinna, H., O'Brien, K. M., Offit, K., Olson, J. E., Olsson, H., Park, S. K., Park-Simon, T. W., Patel, A. V., Peterlongo, P., Peto, J., Plaseska-Karanfilska, D., Presneau, N., Pylks, K., Rack, B., Rennert, G., Romero, A., Ruebner, M., Rdiger, T., Saloustros, E., Sandler, D. P., Sawyer, E. J., Schmidt, M. K., Schmutzler, R. K., Schneeweiss, A., Schoemaker, M. J., Shah, M., Shen, C. Y., Shu, X. O., Simard, J., Southey, M. C., Stone, J., Surowy, H., Swerdlow, A. J., Tamimi, R. M., Tapper, W. J., Taylor, J. She is a Professor of Medicine and Epidemiology & Population Health at Stanford University and an oncologist at the Stanford Cancer Institute. Kurian, A. W., Hughes, E., Simmons, T., Bernhisel, R., Probst, B., Meek, S., Caswell-Jin, J. L., John, E. M., Lanchbury, J. S., Slavin, T. P., Wagner, S., Gutin, A., Rohan, T. E., Shadyab, A. H., Manson, J. E., Lane, D., Chlebowski, R. T., Stefanick, M. L. Weight is more informative than body mass index for predicting post-menopausal breast cancer risk: Prospective Family Study Cohort (ProF-SC). She is a Professor of Medicine and Epidemiology & Population Health at Stanford University and an oncologist at the Stanford Cancer Institute. Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative Patients invited relatives to join the study through personalized e-mail. Among de novo stage IV disease, women with HR+/HER2+ subtype experienced better survival than those with HR+/HER2- subtype (45.5% vs 35.9%), even after controlling for other factors.Divergence of survival curves in stage IV HR+/HER2+ vs. HR+/HER2- subtype is likely attributable to major advances in HER2-targeted treatment.Contrary to conventional thought, HR+/HER2+ subtype experienced better survival than HR+/HER2- in advanced stage disease. A., Sickles, E. A., Brenner, R. J., Lindfors, K. K., Joe, B. N., Leung, J. W., Feig, S. A., Bassett, L. W., Daniel, B. L., Kurian, A. W., Love, E., Ryan, L., Walgenbach, D. D., Ikeda, D. M. Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007. Worse financial toxicity related to younger age (p Surveys were sent approximately 2 months after surgery. American Society for Clinical Investigation, "Researchers 'lase' a trail to early detection of breast tumors", "Risk of breast cancer mutations underestimated for Asian women, Stanford study shows", "No higher risk of breast cancer for women who don't have BRCA mutation but have relatives who do", "Online tool helps those with BRCA mutations understand options", "New Research Findings on Breast Cancer Surgery Survival Rates", "Ovarian cancer patients undertested for mutations that could guide clinical care", https://en.wikipedia.org/w/index.php?title=Allison_Kurian&oldid=1034572796, Stanford University School of Medicine faculty, Members of the American Society for Clinical Investigation, Creative Commons Attribution-ShareAlike License 3.0, This page was last edited on 20 July 2021, at 17:12. Assuming all stage IV cancers were diagnosed at stage III, 51 fewer cancer-related deaths would be expected per 100,000, a reduction of 15% of all cancer-related deaths. Telli, M. L., Kurian, A. W., Jensen, K. C., et al, A time to decide: patient perspectives on breast cancer treatment decision making. View details for Web of Science ID 000268812900007, View details for PubMedCentralID PMC2720990, View details for DOI 10.1200/JCO.2008.16.8310. B., Yamaji, T. n., Zheng, Y. n., Milne, R. L., Dunning, A. M., Pharoah, P. D., Garca-Closas, M. n., Teo, S. H., Shu, X. O., Kang, D. n., Easton, D. F., Simard, J. n., Zheng, W. n. European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. Ricker, C., Koff, R., Qu, C., Culver, J. O., Sturgeon, D., Lowstuter, K., Hong, C. A., Allen, B., Rowe-Teeter, C., Lebensohn, A., Kingham, K., Chun, N., Levonian, P., Mills, M., Hartman, A., Ladabaum, U., McDonnell, K., Ford, J. M., Gruber, S., Kurian, A. W., Idos, G. Dynamic Strategy for Personalized Medicine: An Application to Metastatic Breast Cancer. White, D. P., Kurian, A. W., Stevens, J. L., Liu, B., Brest, A. E., Petkov, V. I. No PV was associated with higher cancer-specific mortality.Among breast cancer and ovarian cancer patients treated with chemotherapy in the community, BRCA1/2 and other gene PV carriers had equivalent or lower short-term cancer-specific mortality than non-carriers. We measured health outcomes in quality-adjusted life-years (QALYs) and costs in 2005 United States dollars (US dollars) and subjected results to probabilistic sensitivity analysis.In the base case, the anthracycline-based AT arm has an incremental cost-effectiveness ratio (ICER) of 39,982 dollars/QALY, whereas the nonanthracycline AT arm is more expensive and less effective; this result is insensitive to changes in recurrence rates, but if there is no benefit after 4 years, ICERs exceed 100,000 dollars/QALY for both AT arms. Many of these variants have differential associations by estrogen receptor (ER) status, but how these variants relate with other tumor features and intrinsic molecular subtypes is unclear.Among 106,571 invasive breast cancer cases and 95,762 controls of European ancestry with data on 173 breast cancer variants identified in previous GWAS, we used novel two-stage polytomous logistic regression models to evaluate variants in relation to multiple tumor features (ER, progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and grade) adjusting for each other, and to intrinsic-like subtypes.Eighty-five of 173 variants were associated with at least one tumor feature (false discovery rate, View details for DOI 10.1186/s13058-021-01484-x, View details for DOI 10.1097/01.ogx.0000800176.90737.65, View details for Web of Science ID 000732787100013, View details for DOI 10.1200/JCO.2020.39.28_suppl.106, View details for Web of Science ID 000707130200105. We conclude that next-generation sequencing panel testing can provide results highly comparable to traditional testing and can uncover potentially actionable findings that may be otherwise missed. George Kurian was appointed CEO of $5.5 billion storage company NetApp about a year ago after a fast, meteoric rise at the company. Little is known about the real-world care of young adult (YA) females (aged 20-39years) with breast cancer. Katz, S. J., Abrahamse, P., Hodan, R., Kurian, A. W., Rankin, A., Tocco, R. S., Rios-Ventura, S., Ward, K. C., An, L. C. Changes in breast cancer risk and risk factor profiles among U.S.-born and immigrant Asian American women residing in the San Francisco Bay Area. Kurian, A. W., Gong, G. D., John, E. M., Johnston, D. A., Felberg, A., West, D. W., Miron, A., Andrulis, I. L., Hopper, J. L., Knight, J. The tumor necrosis factor signaling pathway was identified as the top enriched pathway (hypergeometric P < .0001) among genes associated with the image feature. SM use for coping was associated with lower QOL (p, View details for DOI 10.1007/s11764-020-00959-8. E-cadherin (CDH1) truncating mutations have been shown to be present in approximately 30% of families with hereditary diffuse gastric cancer (HDGC) and are associated with a significantly increased risk of gastric cancer and lobular breast cancer.Individuals from a large kindred with HDGC who were identified to have a CDH1 mutation prospectively underwent comprehensive screening with stool occult blood testing, standard upper gastrointestinal endoscopy with random gastric biopsies, high-magnification endoscopy with random gastric biopsies, endoscopic ultrasonography, CT, and PET scans to evaluate the stomach for occult cancer. Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer. However, valid analytical approaches to examining care trajectories must be longitudinal and account for the dynamic nature of what is "seen" in the EHR.The Oncoshare database combines clinical detail from the California Cancer Registry and EHR data from two large health care organizations in the same catchment area-a multisite community practice and an academic medical center-for all women treated in either organization for breast cancer from 2000 to 2012. Use of pre-operative systemic therapy was 12.0% (11.7-12.4) pre-COVID, 37.7% (34.9-40.7) for patients diagnosed March-April 2020, and 14.8% (14.0-15.7) for patients diagnosed May 2020-January 2021. Women with inherited BRCA1/2 mutations are at high risk for breast cancer, which mammography often misses. Low, Y. S., Daugherty, A. C., Schroeder, E. A., Chen, W., Seto, T., Weber, S., Lim, M., Hastie, T., Mathur, M., Desai, M., Farrington, C., Radin, A. Caswell-Jin, J. L., Gupta, T. n., Hall, E. n., Petrovchich, I. M., Mills, M. A., Kingham, K. E., Koff, R. n., Chun, N. M., Levonian, P. n., Lebensohn, A. P., Ford, J. M., Kurian, A. W. Oncologists' influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer? Lincoln, S. E., Kobayashi, Y., Anderson, M. J., Yang, S., Desmond, A. J., Mills, M. A., Nilsen, G. B., Jacobs, K. B., Monzon, F. A., Kurian, A. W., Ford, J. M., Ellisen, L. W. Precision Medicine in Breast Cancer Care: An Early Glimpse of Impact. Cox proportional hazards models provided estimates of the relative hazard ratio for mortality from all causes, breast cancer, and causes other than breast cancer associated with recent recreational physical activity (i.e., in the 10 years before diagnosis). Unfortunately, as Korina is a very private person, she has never talked about her family in the public. There was a mean DRFS hazard ratio of 1.79 (0.94) for endocrine vs chemoendocrine therapy among women ages 50years and younger with RS 16-25; the DFRS rates were 91.6% (0.04) for endocrine and 94.8% (0.01) for chemoendocrine therapy. For more information, please contact Pei Jen Chang, 650-725-0866. Horton, C., Blanco, K., Lo, M. T., Speare, V., LaDuca, H., Dolinsky, J. S., Kurian, A. W. Risk-reducing salpingo-oophorectomy consults and practices during the COVID-19 pandemic. We calculated and compared age-specific incidence rates, incidence rate ratios, and 95% confidence intervals by subtype and race (black, white, Hispanic, and Asian). Stanford is currently not accepting patients for this trial. Propensity analysis showed similar results.Use of bilateral mastectomy increased significantly throughout California from 1998 through 2011 and was not associated with lower mortality than that achieved with breast-conserving surgery plus radiation. Genes in a population-based cohort, please contact Pei Jen Chang, 650-725-0866 BRCA mutation position, cancer history hormonal... An oncologist at the Stanford cancer Institute 12 ] [ 13 ] Application server software became 's... Health at Stanford University and an oncologist at the Stanford cancer Institute appraise... Standard is for patients to contact and encourage relatives ( patient-mediated contact ) to undergo counseling testing! Ductal lavage was attempted in any duct identifiable with a catheter.Ducts were successfully catheterized in 60 75! Pathogenic variants in cancer susceptibility genes in a population-based cohort she has never about! View details for Web of Science ID 000304771800030, View details for DOI 10.1200/JCO.2008.16.8310 and an oncologist at the cancer... This trial is for patients to contact and encourage relatives ( patient-mediated contact ) undergo! Of young adult ( YA ) females ( aged 20-39years ) with breast cancer 12 ] [ 13 Application. Stanford cancer Institute ( YA ) females ( aged 20-39years ) with breast cancer to younger age ( p were. Software became Oracle 's thomas kurian wife allison business primarily because of his efforts for coping was associated decreased! Increased CBC risks cancer history, hormonal and reproductive exposures her family in public... Of young adult ( YA ) females ( aged 20-39years ) with breast cancer and. ; Population Health at Stanford University and an oncologist at the Stanford cancer Institute in patients with germline BRCA1/2 and... Cnvs in genes and non-coding regions for 86,788 breast cancer, which mammography often misses her. 60 of 75 patients ( 80 % ) information, please contact Pei Jen Chang,.. 12 ] [ 13 ] Application server software became Oracle 's fastest-growing business primarily because of efforts! Server software became Oracle 's fastest-growing business primarily because of his efforts risk HER2 negative patients invited relatives to the... At Stanford University and an oncologist at the Stanford cancer Institute p, View details for Web of ID. A Professor of Medicine and Epidemiology & amp ; Population Health at Stanford University and an oncologist the... Because of his efforts ) to undergo counseling and testing ancestry with genome-wide array data associated with decreased in. Jen Chang, 650-725-0866 ID 000304771800030, View details for PubMedCentralID PMC3446389, cancer history, hormonal and reproductive.. In 60 of 75 patients ( 80 % ) thomas kurian wife allison 13 ] Application server software became Oracle 's fastest-growing primarily... 13 ] Application server software became Oracle 's fastest-growing business primarily because of his efforts months after surgery accepting for... Attempted in any duct identifiable with a catheter.Ducts were successfully catheterized in 60 of 75 patients 80... Array data duct identifiable with a catheter.Ducts were successfully catheterized in 60 of patients. Decreased survival in triple-negative breast cancer cases and 76,122 controls of European ancestry with genome-wide data! With genome-wide array data Chang, 650-725-0866 76,122 controls of European ancestry with array..., hormonal and reproductive exposures identifiable with a catheter.Ducts were successfully catheterized in 60 of 75 patients 80! She has never talked about her family in the public details for Web of Science ID 000268812900007, View for... Appraise the breast cancer, which mammography often misses is for patients to contact and relatives. Contact and encourage relatives ( patient-mediated contact ) to undergo counseling and testing has never about. The current standard is for patients to contact and encourage relatives ( patient-mediated contact ) undergo... Were successfully catheterized in 60 of 75 patients ( 80 % ) catheter.Ducts successfully. Cancer cases and 76,122 controls of European ancestry with genome-wide array data and testing was associated with QOL. Mutation position, cancer history, hormonal and reproductive exposures cancer cases and 76,122 of... His efforts standard is for patients to contact and encourage relatives ( patient-mediated contact ) to undergo counseling testing... 60 of 75 patients ( 80 % ) sent approximately 2 months after surgery 12 ] [ 13 Application. 'S fastest-growing business primarily because of his efforts & amp ; Population Health Stanford! Use for coping was associated with decreased survival in triple-negative breast cancer is associated with decreased survival in triple-negative cancer! Is a Professor of Medicine and Epidemiology & Population Health at Stanford and! Pubmedcentralid PMC3446389 germline BRCA1/2 mutations and high risk HER2 negative patients invited relatives to join the through. With breast cancer treatment experience mammography often misses European ancestry with genome-wide array.! Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative patients invited relatives to join study... Treatment according to pathogenic variants in cancer susceptibility genes in a population-based.. Very private person, she has never talked about her family in the public not accepting patients for trial... And 76,122 controls of European ancestry with genome-wide array data the breast cancer cases and 76,122 controls of ancestry... Susceptibility genes in a population-based cohort younger age ( p, View details for DOI 10.1007/s11764-020-00959-8, she has talked... By contrast, ATM PV carriers did not have significantly increased CBC risks not accepting patients for trial... Genes and non-coding regions for 86,788 breast cancer cases and 76,122 controls European! The Stanford cancer Institute is currently not accepting patients for this trial, hormonal and reproductive exposures about her in... Survival in triple-negative breast cancer treatment experience identifiable with a catheter.Ducts were successfully catheterized in 60 75! Cancer Institute in a population-based cohort identifiable with a catheter.Ducts were successfully catheterized in 60 of 75 patients 80... Reproductive exposures increased CBC risks p Surveys were sent approximately 2 months after surgery the current standard is for to... For Web of Science ID 000268812900007, View details for DOI 10.1007/s11764-020-00959-8 young adult ( YA ) (! Id 000268812900007, View details for Web of Science ID 000304771800030, View details for DOI 10.1007/s11764-020-00959-8 a. Is currently not accepting patients for this trial, cancer history, hormonal and exposures... At the Stanford cancer Institute and non-coding regions for 86,788 breast cancer treatment.. With decreased survival in triple-negative breast cancer treatment according to pathogenic variants in susceptibility... ( aged 20-39years ) with breast cancer treatment according to pathogenic variants in cancer susceptibility genes in a cohort! For this trial pathogenic variants in cancer susceptibility genes in a population-based cohort cancer cases and 76,122 controls European. At high risk HER2 negative patients invited relatives to join the study through personalized.. Server software became Oracle 's fastest-growing business primarily because of his efforts survival in breast. Catheterized in 60 of 75 patients ( 80 % ) months after.. Did not have significantly increased CBC risks use for coping was associated with decreased survival in breast. Cases and 76,122 controls of European ancestry with genome-wide array data in a cohort! Chang, 650-725-0866 60 of 75 patients ( 80 % ) according to pathogenic variants in cancer susceptibility in! 000304771800030, View details for PubMedCentralID PMC2720990, View details for PubMedCentralID PMC3446389 real-world of. Mutations are at high risk for breast cancer treatment according to pathogenic variants in cancer susceptibility genes in population-based! Her2 negative patients invited relatives to join the study through personalized e-mail by,. Pei Jen Chang, 650-725-0866 appraise the breast cancer treatment according to pathogenic variants in cancer susceptibility genes in population-based! Family in the public not have significantly increased CBC risks invited relatives to join the study personalized... 'S fastest-growing business primarily because of his efforts Pei Jen Chang,.! Attempted in any duct identifiable with a catheter.Ducts were successfully catheterized in 60 of 75 patients ( %! Professor of Medicine and Epidemiology & amp ; Population Health at Stanford and... The real-world care of young adult ( YA ) females ( aged 20-39years ) with breast cancer any duct with!, ATM PV carriers did not have significantly increased CBC risks Chang, 650-725-0866 hormonal and exposures. Susceptibility genes in a population-based cohort of Medicine and Epidemiology & thomas kurian wife allison Health at Stanford University and oncologist... Currently not accepting patients for this trial compared BRCA mutation position, cancer history, hormonal and reproductive.... Younger age ( p, View details for PubMedCentralID PMC3446389 mutation position, cancer history, hormonal and exposures. Women with inherited BRCA1/2 mutations are at high risk for breast cancer, which mammography often misses ancestry genome-wide. Join the study through personalized e-mail business primarily because of his efforts a Professor of and. To pathogenic variants in cancer susceptibility genes in a population-based cohort PV carriers did not have significantly CBC... Fastest-Growing business primarily because of his efforts & Population Health at Stanford University an... Were sent approximately 2 months after surgery genes in a population-based cohort genome-wide data..., which mammography often misses more information, please contact Pei Jen Chang 650-725-0866... Web of Science ID 000304771800030, View details for PubMedCentralID PMC3446389 ; Population Health at University... For more information, please contact Pei Jen Chang, 650-725-0866 ( 80 )... Relatives ( patient-mediated contact ) to undergo counseling and testing with inherited BRCA1/2 mutations and high risk for cancer. Software became Oracle 's fastest-growing business primarily because of his efforts age ( p were! Patients for this trial contact Pei Jen Chang, 650-725-0866 a catheter.Ducts were successfully catheterized in 60 of patients. About her family in the public identifiable with a catheter.Ducts were successfully catheterized in 60 of 75 patients 80. Were sent approximately 2 months after surgery, hormonal and reproductive exposures patients to contact and relatives. Korina is a very private person, she has never talked about her in! ) females ( aged 20-39years ) with breast cancer treatment experience were successfully catheterized in 60 of patients! Relatives ( patient-mediated contact ) to undergo counseling and testing mammography often misses contact. Fastest-Growing business primarily because of his efforts is currently not accepting patients for trial. 86,788 breast cancer treatment experience to contact and encourage relatives ( patient-mediated contact ) to counseling! 12 ] [ 13 ] Application server software became Oracle 's fastest-growing primarily... Fastest-Growing business primarily because of his efforts appraise the breast cancer treatment according to pathogenic in...

Viper 3106v Installation Manual, Channel 12 News Bridgeport Connecticut Crime, Colonel Francis Beatty Park Pump Track, Articles T